https://orcid.org/0000-0003-3352-0902
Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Amer M Zeidan, Rami S Komrokji & Andrew M Brunner. (2021) TIM-3 pathway dysregulation and targeting in cancer. Expert Review of Anticancer Therapy 21:5, pages 523-534.
Read now
Read now
Jan Philipp Bewersdorf & Amer M. Zeidan. (2020) Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?. Expert Review of Hematology 13:10, pages 1131-1142.
Read now
Read now
Jan Philipp Bewersdorf & Amer M. Zeidan. (2020) Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?. Leukemia & Lymphoma 61:10, pages 2295-2312.
Read now
Read now
Articles from other publishers (21)
Hongwei Tang, Ying Chen, Nan Zhang, Jianchuan Deng & Kang Zhou. (2023) Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy. Annals of Hematology 102:12, pages 3401-3412.
Crossref
Crossref
Ruchi Yadav, Narek Hakobyan & Jen-Chin Wang. (2023) Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature. International Journal of Molecular Sciences 24:15, pages 12502.
Crossref
Crossref
Başak Aru, Cemil Pehlivanoğlu, Zeynep Dal, Nida Nur Dereli-Çalışkan, Ege Gürlü & Gülderen Yanıkkaya-Demirel. (2023) A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia. Frontiers in Immunology 14.
Crossref
Crossref
Simona Pagliuca, Carmelo Gurnari, Keman Zhang, Tariq Kewan, Waled Bahaj, Minako Mori, Ishani Nautiyal, Marie Thérèse Rubio, Francesca Ferraro, Jaroslaw P. Maciejewski, Li Wang & Valeria Visconte. (2022) Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value. International Journal of Molecular Sciences 23:23, pages 14885.
Crossref
Crossref
Luca Mazzarella, Gunilla Enblad, Johanna Olweus, Karl‐Johan Malmberg & Mats Jerkeman. (2021) Advances in immune therapies in hematological malignancies. Journal of Internal Medicine 292:2, pages 205-220.
Crossref
Crossref
Margarida Silva, Diana Martins & Fernando Mendes. (2022) The Role of Immune Checkpoint Blockade in Acute Myeloid Leukemia. Onco 2:3, pages 164-180.
Crossref
Crossref
Marina Gómez-Llobell, Andrés Peleteiro Raíndo, Jose Climent Medina, Ignacio Gómez Centurión & Adrián Mosquera Orgueira. (2022) Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis. Frontiers in Oncology 12.
Crossref
Crossref
Amer M. ZeidanIsaac BossC. L. BeachWilbert B. CopelandEthan ThompsonBrian A. Fox, Vanessa E. HasleKen Ogasawara, James CavenaghLewis R. SilvermanMaria Teresa Voso, Andrzej HellmannMar Tormo, Tim O’ConnorAlessandro PrevitaliShelonitda RoseGuillermo Garcia-Manero. (2022) A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Advances 6:7, pages 2207-2218.
Crossref
Crossref
Katsuhiro Togami, Sun Sook Chung, Vikas Madan, Christopher A.G. Booth, Christopher M. Kenyon, Lucia Cabal-Hierro, Justin Taylor, Sunhee S. Kim, Gabriel K. Griffin, Mahmoud Ghandi, Jia Li, Yvonne Y. Li, Fanny Angelot-Delettre, Sabeha Biichle, Michael Seiler, Silvia Buonamici, Scott B. Lovitch, Abner LouissaintJrJr, Elizabeth A. Morgan, Fabrice Jardin, Pier Paolo Piccaluga, David M. Weinstock, Peter S. Hammerman, Henry Yang, Marina Konopleva, Naveen Pemmaraju, Francine Garnache-Ottou, Omar Abdel-Wahab, H. Phillip Koeffler & Andrew A. Lane. (2022)
Sex-Biased
ZRSR2
Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
. Cancer Discovery 12:2, pages 522-541.
Crossref
Crossref
Naveen Pemmaraju, Natalie C. Chen & Srdan Verstovsek. (2021) Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America 35:2, pages 409-429.
Crossref
Crossref
Chryssoula Kordella, Eleftheria Lamprianidou & Ioannis Kotsianidis. (2021) Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter. Frontiers in Oncology 11.
Crossref
Crossref
Saeid Taghiloo & Hossein Asgarian-Omran. (2021) Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. Critical Reviews in Oncology/Hematology 157, pages 103164.
Crossref
Crossref
Jan Philipp Bewersdorf, Rory M. Shallis & Amer M. Zeidan. (2021) Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews 45, pages 100709.
Crossref
Crossref
Xavier Roussel, Etienne Daguindau, Ana Berceanu, Yohan Desbrosses, Walid Warda, Mathieu Neto da Rocha, Rim Trad, Eric Deconinck, Marina Deschamps & Christophe Ferrand. (2020) Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Frontiers in Oncology 10.
Crossref
Crossref
Jan Philipp Bewersdorf & Amer M. Zeidan. (2020) Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?. Best Practice & Research Clinical Haematology 33:4, pages 101222.
Crossref
Crossref
Vickie R. Shannon, Ronald Anderson, Ada Blidner, Jennifer Choi, Tim Cooksley, Michael Dougan, Ilya Glezerman, Pamela Ginex, Monica Girotra, Dipti Gupta, Douglas B. Johnson, Maria E. Suarez-Almazor & Bernardo L. Rapoport. (2020) Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer 28:12, pages 6145-6157.
Crossref
Crossref
Rory M. Shallis, Prajwal C. Boddu, Jan Philipp Bewersdorf & Amer M. Zeidan. (2020) The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Reviews 40, pages 100639.
Crossref
Crossref
Jan Philipp Bewersdorf, Hetty Carraway & Thomas Prebet. (2020) Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic Advances in Hematology 11, pages 204062072095500.
Crossref
Crossref
A. John Barrett. (2019) Acute myeloid leukaemia and the immune system: implications for immunotherapy. British Journal of Haematology 188:1, pages 147-158.
Crossref
Crossref
Thomas Mercher & Juerg Schwaller. (2019) Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Frontiers in Pediatrics 7.
Crossref
Crossref
Darina Ocadlikova, Mariangela Lecciso, Alessandro Isidori, Federica Loscocco, Giuseppe Visani, Sergio Amadori, Michele Cavo & Antonio Curti. (2019) Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. Frontiers in Oncology 9.
Crossref
Crossref